Identifying distinct trajectories of change in young breast cancer survivors' sexual functioning.
Adolescent
Adult
Antineoplastic Agents, Hormonal
/ therapeutic use
Anxiety
/ epidemiology
Body Image
/ psychology
Breast Neoplasms
/ metabolism
Cancer Survivors
Cohort Studies
Disease Progression
Female
Humans
Leuprolide
/ therapeutic use
Neoplasm Staging
Ovariectomy
/ statistics & numerical data
Quality of Life
Receptors, Estrogen
/ metabolism
Risk Factors
Severity of Illness Index
Sexual Dysfunction, Physiological
/ epidemiology
Sexual Dysfunctions, Psychological
/ epidemiology
Sexual Partners
Tamoxifen
/ therapeutic use
Young Adult
breast cancer
cancer
cancer survivorship
oncology
quality of life
sexual dysfunction
sexual functioning
trajectory analysis
young women
Journal
Psycho-oncology
ISSN: 1099-1611
Titre abrégé: Psychooncology
Pays: England
ID NLM: 9214524
Informations de publication
Date de publication:
05 2019
05 2019
Historique:
received:
08
10
2018
revised:
22
02
2019
accepted:
25
02
2019
pubmed:
1
3
2019
medline:
28
3
2020
entrez:
1
3
2019
Statut:
ppublish
Résumé
To identify and characterize distinct trajectories of change in young women's sexual functioning over the first 5 years following breast cancer diagnosis. Group-based trajectory modeling was applied to the sexual functioning of 896 women diagnosed with stage I-IV breast cancer at age 40 or younger. The Cancer Rehabilitation Evaluation System was used to evaluate women's symptoms of sexual dysfunction annually for 5 years. Five distinct trajectories of sexual functioning were identified: one asymptomatic, one minimally symptomatic, two moderately symptomatic, and one severely symptomatic trajectory. Twelve percent of women were asymptomatic throughout follow-up. The plurality of women experienced stable mild symptoms (42%). Among those with moderate symptoms, some experienced improvement over time (22%) while others experienced deterioration (13%); 11% experienced stable severe symptoms that did not remit over time. Independent predictors of experiencing a symptomatic rather than asymptomatic trajectory (P < 0.05, two-sided) included diagnosis with stage 2 versus 1 disease, ER positive disease treated with oophorectomy or ovarian suppression, being partnered, having anxiety, poorer body image, and greater musculoskeletal pain. We identified distinct trajectories that describe the reported sexual symptoms in this cohort of young breast cancer survivors. The majority of women reported various degrees of sexual dysfunction that remained stable over the study period. There is, however, potential for improvement of moderate and severe symptoms of sexual dysfunction in early survivorship.
Substances chimiques
Antineoplastic Agents, Hormonal
0
Receptors, Estrogen
0
Tamoxifen
094ZI81Y45
Leuprolide
EFY6W0M8TG
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1033-1040Subventions
Organisme : NCI NIH HHS
ID : NIH 3R25CA057711
Pays : United States
Organisme : Susan G. Komen
Pays : United States
Informations de copyright
© 2019 John Wiley & Sons, Ltd.